617 related articles for article (PubMed ID: 19283918)
41. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
42. The role of ovarian ablation in the management of breast cancer.
Wirk B
Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
[TBL] [Abstract][Full Text] [Related]
43. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
44. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
[TBL] [Abstract][Full Text] [Related]
45. Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients.
Ruddy KJ; Partridge AJ
Oncology (Williston Park); 2009 Jan; 23(1):34, 40. PubMed ID: 19283919
[No Abstract] [Full Text] [Related]
46. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
47. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
Prowell TM; Davidson NE
Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
[TBL] [Abstract][Full Text] [Related]
48. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
49. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
50. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
Petrelli F; Barni S
Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
[No Abstract] [Full Text] [Related]
51. The place of chemotherapy in the treatment of early breast cancer.
Buzdar A
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
[TBL] [Abstract][Full Text] [Related]
52. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
53. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
54. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study.
Nystedt M; Berglund G; Bolund C; Fornander T; Rutqvist LE
J Clin Oncol; 2003 May; 21(9):1836-44. PubMed ID: 12721261
[TBL] [Abstract][Full Text] [Related]
55. Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression?
Baum M; O'Shaughnessy JA
Clin Breast Cancer; 2002 Oct; 3(4):260-7. PubMed ID: 12425754
[TBL] [Abstract][Full Text] [Related]
56. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
58. Ovarian ablation as a treatment for breast cancer.
Sainsbury R
Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
[TBL] [Abstract][Full Text] [Related]
59. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
Robertson JF; Blamey RW
Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
